{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:53:56Z","timestamp":1793084036414,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.semarthrit.2020.06.010","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T19:29:10Z","timestamp":1593545350000},"page":"1101-1108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study"],"prefix":"10.1016","volume":"50","author":[{"given":"Luc\u00eda","family":"Lourido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ruiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor","family":"Picchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Diz-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Vilaboa-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio Pinto","family":"Tasende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"P\u00e9rez-Pamp\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mera-Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hambardzumyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saedis","family":"Saevarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.06.010_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.06.010_bib0002","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/acr.20283","article-title":"Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.06.010_bib0003","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.joca.2007.10.006","article-title":"Differential effects of tumor necrosis factor-alpha and interleukin-1beta on cell death in human articular chondrocytes","volume":"16","author":"Carames","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2020.06.010_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","article-title":"Anti-TNF in rheumatoid arthritis: an overview","volume":"165","author":"Radner","year":"2015","journal-title":"Wien Med Wochenschr"},{"issue":"13","key":"10.1016\/j.semarthrit.2020.06.010_bib0005","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.06.010_bib0006","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"issue":"10055","key":"10.1016\/j.semarthrit.2020.06.010_bib0007","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.06.010_bib0008","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/ard.2009.126714","article-title":"Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.06.010_bib0009","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000009","article-title":"Therapeutic implications of autoantibodies in rheumatoid arthritis","volume":"2","author":"Aletaha","year":"2016","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.06.010_bib0011","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/ker010","article-title":"The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study","volume":"50","author":"Klaasen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.06.010_bib0012","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0013","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis","volume":"68","author":"Potter","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.06.010_bib0014","article-title":"Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients","author":"Ling","year":"2019","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.06.010_bib0015","first-page":"701","article-title":"Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-alpha response in rheumatoid arthritis","volume":"29","author":"Vasilopoulos","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.06.010_bib0016","first-page":"1067","article-title":"Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis","volume":"26","author":"Cuchacovich","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.06.010_bib0017","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/rheumatology\/kes184","article-title":"Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis","volume":"51","author":"Canh\u00e3o","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.06.010_bib0018","first-page":"497","article-title":"Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis","volume":"33","author":"Braun-Moscovici","year":"2006","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.06.010_bib0019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10067-011-1679-4","article-title":"The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) alpha-308G\/G promoter polymorphism","volume":"30","author":"Soto","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.06.010_bib0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/rheumatology\/kel262","article-title":"Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab","volume":"46","author":"Lequerr\u00e9","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.06.010_bib0021","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2006.060608","article-title":"High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis","volume":"66","author":"Bobbio-Pallavicini","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.06.010_bib0022","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jbspin.2008.09.010","article-title":"Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis","volume":"76","author":"Bruns","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.27758","volume":"63","author":"Saevarsdottir","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13075-016-1014-1","article-title":"Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking","volume":"18","author":"Roos","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.06.010_bib0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41584-018-0070-0","article-title":"Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction","volume":"14","author":"Holers","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"6220","key":"10.1016\/j.semarthrit.2020.06.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"5 Pt A","key":"10.1016\/j.semarthrit.2020.06.010_bib0027","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.nbt.2015.09.002","article-title":"Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling","volume":"33","author":"Sj\u00f6berg","year":"2016","journal-title":"N Biotechnol"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.06.010_bib0028","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1073\/pnas.1518553113","article-title":"Anoctamin 2 identified as an autoimmune target in multiple sclerosis","volume":"113","author":"Ayoglu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.06.010_bib0029","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1164\/rccm.201407-1341OC","article-title":"Proteomic profiling reveals autoimmune targets in sarcoidosis","volume":"191","author":"H\u00e4ggmark","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.06.010_bib0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nm0302-295","article-title":"Autoantigen microarrays for multiplex characterization of autoantibody responses","volume":"8","author":"Robinson","year":"2002","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.06.010_bib0031","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.21269","article-title":"Antigen microarray profiling of autoantibodies in rheumatoid arthritis","volume":"52","author":"Hueber","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"37","key":"10.1016\/j.semarthrit.2020.06.010_bib0032","doi-asserted-by":"crossref","first-page":"15867","DOI":"10.1073\/pnas.0908032106","article-title":"A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis","volume":"106","author":"Monach","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.06.010_bib0033","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0002-9343(80)90462-3","article-title":"The CREST syndrome: a distinct serologic entity with anticentromere antibodies","volume":"69","author":"Fritzler","year":"1980","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.06.010_bib0034","first-page":"308","article-title":"High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F","volume":"20","author":"Rattner","year":"1997","journal-title":"Clin Invest Med"},{"issue":"14","key":"10.1016\/j.semarthrit.2020.06.010_bib0035","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1073\/pnas.84.14.4979","article-title":"Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B","volume":"84","author":"Earnshaw","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0036","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.autrev.2015.10.001","article-title":"Anti-centromere protein A antibodies in systemic sclerosis: significance and origin","volume":"15","author":"Perosa","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.06.010_bib0037","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/art.1780390813","article-title":"The centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis","volume":"39","author":"Rattner","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.semarthrit.2020.06.010_bib0038","first-page":"1419","article-title":"Anti-centromere autoantibody in a patient evolving from a lupus\/Sjogren's overlap to the CREST variant of scleroderma","volume":"25","author":"Ford","year":"1998","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.06.010_bib0039","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00296-004-0568-4","article-title":"Anti-CENP-H antibodies in patients with Sjogren's syndrome","volume":"26","author":"Hsu","year":"2006","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.06.010_bib0040","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0896-8411(95)90009-8","article-title":"Autoimmunity to the cell cycle-dependent centromere protein p330d\/CENP-F in disorders associated with cell proliferation","volume":"8","author":"Casiano","year":"1995","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0041","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/(SICI)1097-0320(19960901)25:1<90::AID-CYTO10>3.0.CO;2-P","article-title":"Nuclear autoantigen p330d\/CENP-F: a marker for cell proliferation in human malignancies","volume":"25","author":"Landberg","year":"1996","journal-title":"Cytometry"},{"key":"10.1016\/j.semarthrit.2020.06.010_bib0042","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1196\/annals.1313.034","article-title":"Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin's lymphoma","volume":"1050","author":"Bencimon","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.06.010_bib0043","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/ijc.22413","article-title":"CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer","volume":"120","author":"O'Brien","year":"2007","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.06.010_bib0044","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3343\/alm.2019.39.2.227","article-title":"Centromere protein-F-like pattern in a patient with rheumatoid arthritis","volume":"39","author":"Hur","year":"2019","journal-title":"Ann Lab Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1476-4598-12-95","article-title":"Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay","volume":"12","author":"Welner","year":"2013","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0046","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1038\/s41598-017-07137-4","article-title":"Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis","volume":"7","author":"Kuramoto","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.06.010_bib0047","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.autrev.2010.09.025","article-title":"Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F","volume":"10","author":"Fritzler","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.06.010_bib0048","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"group Bs. Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.06.010_bib0049","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3109\/14397595.2016.1153567","article-title":"Association of anti-Ro\/SSA antibody with response to biologics in patients with rheumatoid arthritis","volume":"26","author":"Hagiwara","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.06.010_bib0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.semarthrit.2019.02.003","article-title":"Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis","volume":"49","author":"Ishikawa","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.06.010_bib0051","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1186\/ar3546","article-title":"Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study","volume":"13","author":"Yukawa","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.06.010_bib0052","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3899\/jrheum.101295","article-title":"Anti-Ro\/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis","volume":"38","author":"Matsudaira","year":"2011","journal-title":"J Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220301906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220301906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:06:25Z","timestamp":1758733585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220301906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0049017220301906"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.06.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}